Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. (Q52881948)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Haifa Kathrin Al-Ali

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

19

G Ehninger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1

U Platzbecker

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

N Gattermann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

D Haase

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

V Janzen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

J Krauter

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

K Götze

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Schlenk

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

F Nolte

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Letsch

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Kündgen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Lübbert

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

U Germing

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Wermke

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

H Reinhard

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

C Weiss

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

K Lieder

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

O Leismann

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Giagounidis

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

4 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

696-698

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2013.325

29 February 2020

exact match

0 references

cites work

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Clinical effect of point mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.325

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24186004

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24186004

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2013.325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24186004%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference